FDA GRAS notification is the proposal to replace self-affirmed GRAS review with a mandatory pre-market filing to FDA for every new food ingredient — and attorney Todd Harrison of Venable argues, via NutraIngredients, that FDA likely lacks the statutory authority to impose it without formal rulemaking.
What GRAS means today, and what the proposal changes
GRAS stands for Generally Recognized As Safe — the status that exempts an ingredient from the full food-additive petition process. Since 1997, FDA has allowed companies to self-affirm GRAS status internally, using a qualified expert panel, without ever notifying FDA. Most new food and beverage ingredients on the US market today rely on this pathway. The proposal under discussion would require an FDA GRAS notification before market entry — moving closer to the pre-1997 approval model.
Self-affirmed GRAS vs. FDA GRAS notification
| Factor | Self-affirmed GRAS | FDA GRAS notification |
|---|---|---|
| Who reviews safety | Manufacturer / independent expert panel | FDA, pre-market |
| Notification to FDA | Optional | Mandatory before launch |
| Typical timeline | Controlled internally | Subject to FDA review queue |
| Documentation burden | Internal safety dossier | Regulator-grade filing dossier |
| FDA’s legal exposure | Low — within existing framework | High, per Harrison’s argument |
Why the legal challenge matters more than the policy
Harrison’s point is procedural, not political: FDA’s own regulations currently permit self-affirmation as a valid pathway. Converting that into a mandatory notification requirement without going through full notice-and-comment rulemaking invites exactly the kind of challenge that has unwound other agency rules in recent years. Expect this to be contested in court well before it becomes enforceable — a process that can run for years.
What this means beyond the US
For ingredient suppliers and formulators across Southeast Asia — Thailand, Vietnam, Indonesia — the immediate risk isn’t the eventual ruling. It’s the interim uncertainty for any SKU in a US-bound pipeline. New-ingredient launch timelines built around self-affirmation may not hold if notification becomes mandatory mid-project, and documentation adequate for internal self-affirmation may not be adequate for a regulator-facing filing.
What to do now, regardless of the legal outcome
- Audit which US-bound SKUs currently rely on self-affirmed GRAS conclusions, and how thin the underlying dossier is.
- Strengthen safety documentation to filing-grade quality now, rather than under deadline pressure later.
- Track the litigation through credible industry sources such as NutraIngredients rather than assuming a fixed effective date.
FAQ
When would FDA GRAS notification take effect?
No firm date has been set. The proposal is still under consideration and is widely expected to face legal challenges before any mandatory effective date.
Would ingredients already self-affirmed need to be re-filed?
Retroactive effect is unclear at this stage. Suppliers should monitor the formal rulemaking record and prepare documentation in advance rather than wait for clarity.
Does this affect suppliers outside the US?
Yes, directly, if their ingredients or finished products move into the US market through any part of the supply chain, even indirectly.
How DIC supports this
DIC maintains structured documentation and specification records for the ingredients we import and distribute across the region, alongside a dedicated pharma-grade warehouse for products requiring tighter handling controls. For manufacturers reviewing their own ingredient documentation in light of regulatory shifts like this one, our team is available for a supply and specification conversation through the contact form on our website.
